4 recruiting, 2 active not recruiting, 2 not yet recruiting, 1 completed. 12 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 4, Active not recruiting 2, Not yet recruiting 2, Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Recruiting 2, Terminated 1, Unknown 1 |
Follow Advanced Prostate Cancer: new trials by email Literature Review of Advanced Prostate Cancer trials Research Report on Advanced Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Study of XNW5004 Tablets in Advanced Prostate Cancer XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone, XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone, XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID - Advanced Prostate Cancer | Phase 2 | Not yet recruiting | Evopoint Biosciences Inc. | 242 | 2026-07-13 | 2026-07-28 |
| A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer Teverelix DP 180 mg - Advanced Prostate Cancer, GnRH Antagonist | Phase 2 | Not yet recruiting | Antev Ltd. | 40 | 2026-07-01 | 2026-03-12 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer GDC-1261 - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Genentech, Inc. | 260 | 2026-04-29 | 2026-10-06 |
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Darolutamide, Relugolix - Prostate Cancer, Advanced Prostate Cancer | Phase 2 | Active not recruiting | Atish Choudhury, MD | 33 | 2024-12-13 | 2026-03-09 |
| PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. Stereotactic Body Radiation Therapy - Advanced Prostate Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2024-06-27 | 2026-08-21 |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer HRS-4357 injection - Advanced Prostate Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 49 | 2023-09-30 | 2023-08-23 |
| SRAM study_Postate Cancer Conventional IMRT, SBRT - Advanced Prostate Cancer | Phase 2 | Active not recruiting | CCTU | 120 | 2019-05-15 | 2026-03-04 |
| Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Nivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer - Advanced Metastatic Cancer, Advanced Prostate Cancer | Phase 2 | Completed | Parker Institute for Cancer Immunotherapy | 100 | 2018-10-17 | 2024-02-07 |
| Study of HPN424 in Patients With Advanced Prostate Cancer HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target - Advanced Prostate Cancer | Phase 1 / Phase 2 | Terminated | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 104 | 2018-07-24 | 2024-02-14 |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel BKM 120, Cabazitaxel - Advanced Prostate Cancer | Phase 2 | Withdrawn | SCRI Development Innovations, LLC | 2014-04-01 | 2016-02-11 |
Prostatic Neoplasms (4) · Neoplasm Metastasis (1) · Prostatic Diseases (1) · Urogenital Diseases (1)
Genital Diseases (5) · Genital Diseases, Male (5) · Male Urogenital Diseases (5) · Neoplasms (5) · Genital Neoplasms, Male (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Abiraterone Acetate (2) · Prednisone (2) · enzalutamide (2) · BID protein, human (1) · Docetaxel (1) · Ipilimumab (1) · Lead (1) · Leuprolide (1) · NVP-BKM120 (1) · Nivolumab (1) · Photons (1) · Pluvicto (1) · Postprandial Period (1) · Radiosurgery (1) · Random Allocation (1)
Antev Ltd. (1) · Atish Choudhury, MD (1) · CCTU (1) · Evopoint Biosciences Inc. (1) · Genentech, Inc. (1) · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Parker Institute for Cancer Immunotherapy (1) · Qilu Pharmaceutical Co., Ltd. (1) · SCRI Development Innovations, LLC (1)
United States (7) · United Kingdom (2) · Australia (1) · China (1) · Hong Kong (1)
Atish Choudhury, MD, PhD (1) · Comron Hassanzadeh, MD (1) · John D. Hainsworth, M.D. (1) · Matthew K. Tollefson, MD (1)